×
Home Current Archive Editorial board
News Contact
Pregledni rad – Review Paper

PHARAMACEUTICAL HYALURONIC ACID BASED CARRIERS FOR PARENTERAL USE, PARTICULARLY CONJUGATES WITH TAXOL: A REVIEW

By
Nada Ćujić ,
Nada Ćujić

Institute for Medicinal Plant Reasearch „Dr Josif Pančić“, Belgrade, Serbia

Svetlana Ibrić ,
Svetlana Ibrić

Department for pharmaceutical technology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

Dubravka Bigović ,
Dubravka Bigović

Institute for Medicinal Plant Reasearch „Dr Josif Pančić“, Belgrade, Serbia

Nebojša Noveski ,
Nebojša Noveski

Institute for Medicinal Plant Reasearch „Dr Josif Pančić“, Belgrade, Serbia

Katarina Šavikin
Katarina Šavikin

Institute for Medicinal Plant Reasearch „Dr Josif Pančić“, Belgrade, Serbia

Abstract

In recent years, drug delivery systems are especially interesting because they allow therapeutic efficiency and reduce side effects. Conjugates of hyaluronic acid and chemotherapeutic agents, especially taxol, have been recognized as excellent solution for many therapeutic indications. The aim of conjugation of taxol with hyaluronic acid was the toxicity reduction on healthy cells and increase of selectivity on tumor cells. Hyaluronic acid could be used in various pharmaceutical preparations, also in parenteral, because of its biocompatibility and biodegradability. Hyaluronic acid as a carrier belongs to in situ gelling systems, which is passing a phase transition in response to external conditions such as temperature, different pH value or the presence of ions, enabling prolonged effect of the drug substances. Many tumor cells have a large number of receptors for hyaluronic acid, which has a great affinity for the tumor cells. The incorporation of taxol in gelling system of hyaluronic acid provides sustained drug release, increased anticancer activity, reduced damage of healthy cells and increased selectivity on cancer cells.


 

References

[{"id":1609,"citationNumber":"1.","type":"article-journal","title":"A Paclitaxel Hyaluronanbioconjugatetargetingovariancanceraffords a potent in vivotherapeuticactivity","DOI":null,"author":[{"given":"A.","family":"Banzato"},{"given":"S.","family":"Bobisse"},{"given":"M.","family":"Rondina"},{"given":"D.","family":"Renier"},{"given":"F.","family":"Bettella"},{"given":"G.","family":"Esposito"},{"given":"L.","family":"Quintieri"},{"given":"L.Melendez","family":"Alafort"},{"given":"U.","family":"Mazzi"},{"given":"P.","family":"Zanovello"},{"given":"A.","family":"Rosato"}],"issued":{"date-parts":["2008"]},"container-title":"Clinical Cancer Research","volume":"14","issue":null,"page":"3598\u20133606"}]

[{"id":1610,"citationNumber":"2.","type":"book","title":"H. P. Rang, M.M. Dale, J.M. Ritter, R. Flower, Elsevier Health Sciences, Churchill Livingstone","DOI":null,"author":[{"given":"Rang","family":""},{"given":"Dale\u2019s","family":"Pharmacology"},{"given":"H.P.","family":"Rang"},{"given":"M.M.","family":"Dale"},{"given":"J.M.","family":"Ritter"},{"given":"R.","family":"Flower"}],"issued":{"date-parts":["2007"]},"container-title":null,"volume":null,"issue":null,"page":"6 ,"}]

[{"id":1611,"citationNumber":"3.","type":"book","title":"The Complete Drug Reference","DOI":null,"author":[{"given":"Martindale","family":""}],"issued":{"date-parts":["2009"]},"container-title":"Sean C Sweetman, London, Chicago, Pharmaceutical Press","volume":null,"issue":null,"page":null}]

[{"id":1612,"citationNumber":"4.","type":"article-journal","title":"","DOI":null,"author":[{"given":"PDR (Physicians Desk References) for Herbal Medicines","family":""}],"issued":{"date-parts":["2005"]},"container-title":"Medical Economics Company, Thomson at Montvale NJ.","volume":"3","issue":null,"page":null}]

[{"id":1613,"citationNumber":"5.","type":"article-journal","title":"Biotech History: Yew trees, paclitaxel synthesis and fungi","DOI":null,"author":[{"given":"R.","family":"Renneberg"}],"issued":{"date-parts":["2007"]},"container-title":"Biotech Journl","volume":"2","issue":"10","page":"1207\u20131209"}]

[{"id":1614,"citationNumber":"6.","type":"article-journal","title":"Intralymphatic chemotherapy using a hyaluron an-cisplatin conjugate","DOI":null,"author":[{"given":"S.","family":"Cai"},{"given":"Y.","family":"Xie"},{"given":"T.R.","family":"Bagby"},{"given":"M.S.","family":"Cohen"},{"given":"M.L.","family":"Forrest"}],"issued":{"date-parts":["2008"]},"container-title":"Journal Surgery Research","volume":"147","issue":"2","page":"247\u2013252"}]

[{"id":1615,"citationNumber":"7.","type":"book","title":"Merck & Co Inc. Whitehouse Station, NJ","DOI":null,"author":[{"given":"The","family":"MerckIndex"}],"issued":{"date-parts":["1996"]},"container-title":null,"volume":"12","issue":null,"page":null}]

[{"id":1616,"citationNumber":"8.","type":"article-journal","title":"Intra-articular hyaluronic acid injections for knee osteoarthritis","DOI":null,"author":[{"given":"D.Y.","family":"Wen"}],"issued":{"date-parts":["2000"]},"container-title":"Am Fam Physician","volume":"62","issue":"3","page":"565\u2013570"}]

[{"id":1617,"citationNumber":"9.","type":"article-journal","title":"Biodegradable injectable in situ depot forming drug delivery systems","DOI":null,"author":[{"given":"D.","family":"Chitkara"},{"given":"A.","family":"Shikanov"},{"given":"N.","family":"Kumar"},{"given":"A.J.","family":"Domb"}],"issued":{"date-parts":["2006"]},"container-title":"Macromolecul Bioscience","volume":"6 :977\u2013990","issue":null,"page":null}]

[{"id":1618,"citationNumber":"10.","type":"article-journal","title":"Injectable hydrogels as unique biomedical materials","DOI":null,"author":[{"given":"L.","family":"Yu"},{"given":"J.","family":"Ding"}],"issued":{"date-parts":["2008"]},"container-title":"The Royal Society of Chemistry","volume":"37","issue":null,"page":"1473\u20131481"}]

[{"id":1619,"citationNumber":"11.","type":"article-journal","title":"Organogels and their use in drug delivery \u2014 A review","DOI":null,"author":[{"given":"A.","family":"Vintiloiu"},{"given":"J.C.","family":"Leroux"}],"issued":{"date-parts":["2008"]},"container-title":"Journal of Controlled Release","volume":"125","issue":null,"page":"179\u2013192"}]

[{"id":1620,"citationNumber":"12.","type":"article-journal","title":"In situ forming parenteral drug delivery systems: an overview","DOI":null,"author":[{"given":"C.B.","family":"Packhaeuser"},{"given":"J.","family":"Schnieders"},{"given":"C.G.","family":"Oster"},{"given":"T.","family":"Kissel"}],"issued":{"date-parts":["2004"]},"container-title":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"58","issue":null,"page":"445\u2013455"}]

[{"id":1621,"citationNumber":"13.","type":"article-journal","title":"Priru\u010dnik za ve\u017ebe iz farmaceutske tehnologije sa biofarmacijom, Oblast: Sterilni lekoviti preparati, Farmaceutski fakultet","DOI":null,"author":[{"given":"J.","family":"Mili\u0107"},{"given":"M.","family":"Primorac"},{"given":"M.","family":"Stupar"}],"issued":{"date-parts":["2005"]},"container-title":null,"volume":null,"issue":null,"page":null}]

[{"id":1622,"citationNumber":"14.","type":"book","title":"","DOI":null,"author":[{"given":"Handbook","family":"Pharmaceutical Excipients"}],"issued":{"date-parts":["2009"]},"container-title":"The Pharmaceutical Press, London, American Pharmaceutical Association, Washington.","volume":"6","issue":null,"page":null}]

[{"id":1623,"citationNumber":"15.","type":"article-journal","title":"European Directorate for the Quality of Medicines","DOI":null,"author":[{"given":"European","family":"Pharmacopoeia"}],"issued":{"date-parts":["2011"]},"container-title":null,"volume":null,"issue":null,"page":null}]

[{"id":1624,"citationNumber":"16.","type":"article-journal","title":"Savezni zavod za za\u0161titu i unapre\u0111enje zdravlja, Savremena administracija","DOI":null,"author":[{"given":"Jugoslovenska","family":"farmakopeja"},{"given":"Peto","family":"izdanje"}],"issued":{"date-parts":["2000"]},"container-title":null,"volume":null,"issue":null,"page":null}]

[{"id":1625,"citationNumber":"17.","type":"book","title":"Handbook of pharmaceutical manufacturing formulations","DOI":null,"author":[{"given":"S.K.","family":"Niazi"}],"issued":{"date-parts":["2004"]},"container-title":null,"volume":"6","issue":null,"page":null}]

[{"id":1626,"citationNumber":"18.","type":"article-journal","title":"Guidance for Industry, Sterile Drug Products, Produced by Aseptic ProcessingCurrent Good Manufacturing Practice (2004): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research","DOI":null,"author":[],"issued":{"date-parts":["2004"]},"container-title":null,"volume":null,"issue":null,"page":null}]

Citation

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.